<DOC>
	<DOC>NCT01286909</DOC>
	<brief_summary>A trial of LaFlavon in Patients with Metabolic Syndrome to Evaluate its Effectiveness in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL).</brief_summary>
	<brief_title>Efficacy of Laflavon in Lowering Triglycerides and Raising High-Density Lipoprotein (HDL)</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Lycopene</mesh_term>
	<criteria>1. Men and Women with Metabolic Syndrome 2. Elevated Triglycerides (&gt; 150) 3. Low HighDensity Lipoprotein (HDL) (&lt; 35) 4. Willingness to take study nutritional supplement once a day for 3 months 1. Women who are pregnant, nursing, or who intend pregnancy during the period of treatment 2. Known milk, soy or whey allergy</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Metabolic</keyword>
</DOC>